Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Date:5/4/2011

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced it will report first quarter 2011 financial results after the NASDAQ Global Select Market closes on Tuesday, May 10, 2011. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the first quarter 2011 and to provide a business and financial update.

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' First Quarter 2011 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the New Drug Application (NDA) for lorcaserin.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's clinical trials and other studies, including for lorcaserin, may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's resubmission of the lorcaserin NDA may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersJack Lief

David Schull, PresidentPresident and CEO

david.schull@russopartnersllc.com858.717.2310Cindy McGeeManager, IR and Corporate Communications

Anthony J. Russo, Ph.D., CEO858.453.7200, ext. 1479

tony.russo@russopartnersllc.com212.845.4251www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
2. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
3. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
4. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
5. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
7. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
8. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
9. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
10. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
11. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... of the Best Places to Work in the Research Triangle for 2017. , ... nominated, a company had to meet a threshold in employee participation--a percentage that ...
(Date:9/20/2017)... ... 2017 , ... Demand generation pioneer True Influence has announced ... The Marketing Tech Conference October 2–4, at the Hynes Convention Center in Boston, ... representing such thought-leading companies as JP Morgan Chase, GE Digital, and Dun & ...
(Date:9/20/2017)... ... ... In just a short time since going on sale on Wal-Mart Stores-owned ... trying the product for the first time, and others who had already been using ... Moore, MD, for everyone from athletes at risk from multiple concussions to elderly consumers ...
(Date:9/20/2017)... ... September 20, 2017 , ... Health & Safety Institute (HSI) ... HAZWOPER 8-, 24- and 40-Hour courses from now until November 30, 2017 to assist ... offering these discounted prices to all businesses and government agencies – whether or not ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm ... Friday, September 8, and Monday, September 11, off work and rolled up their sleeves ... before heading to local homes to start the process of rebuilding. , CORDA founder ...
Breaking Medicine News(10 mins):